Skip to content
Search

Latest Stories

Final Report: Cass review suggests 32 recommendations for children's gender care

Final Report: Cass review suggests 32 recommendations for children's gender care
The review highlights "unclear" evidence supporting the "impact of Puberty Suppressing Hormones on cognitive and psychosexual development" as part of  children's gender care

A final review of gender services provided by the NHS has uncovered significant shortcomings, leaving thousands of vulnerable children questioning their gender identity without adequate support.

The report, led by Dr. Hilary Cass, a prominent consultant paediatrician, highlights the use of unproven treatments and the detrimental impact of the polarized trans debate on gender care provision.


The investigation, commissioned by NHS England in 2020, focused on the Tavistock and Portman NHS mental health trust’s gender identity development services (Gids), which treated around 9,000 children and young people between 2009 and 2020.

Shockingly, the review found that despite limited evidence of effectiveness and potential health risks, puberty blockers and cross-sex hormones were routinely administered.

Dr. Cass emphasized that the "rationale for early puberty suppression remains unclear, with weak evidence regarding the impact on gender dysphoria, mental or psychosocial health. The effect on cognitive and psychosexual development remains unknown."

She highlighted the toxic nature of the public discourse surrounding gender issues, which has hindered open discussion and led to the misrepresentation of research findings.

In response to the report's findings, NHS England has taken decisive action, closing Gids and adopting a "holistic" approach to care.

Under the new model, psychological support will take precedence over medical intervention for under-18s grappling with gender identity issues.

The emphasis is on personalized care plans, including thorough assessments for neurodevelopmental conditions like ADHD, autism, and other mental health conditions.

The report also called for caution in the "use of masculinizing/feminizing hormones", particularly for individuals under 18, stressing the need for clear clinical justifications for such treatments.

It also highlighted the need for "provision for people considering detransition, recognising that they may not wish to re-engage with the services whose care they were previously under."

A spokesperson for the NHSE said, "the NHS is bringing forward its systemic review of adult gender services and has written to local NHS leaders to ask them to pause offering first appointments at adult gender clinics to young people below their 18th birthday.”

In conclusion, the report signals a pivotal moment for NHS gender services, recommending up to 32 suggestions to shift to evidence-based care for children dealing with gender dysphoria.

More For You

RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less